Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Condition:   HIV Infections Interventions:   Biological: CH505TF gp120;   Biological: GLA-SE adjuvant;   Biological: Placebo Sponsors:   HIV Vaccine Trials Network;   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials